Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Accured Expenses (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Change in Accured Expenses for 7 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 75.29% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.2 million through Dec 2025, down 419.6% year-over-year, with the annual reading at -$12.2 million for FY2025, 419.6% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$1.5 million at Pliant Therapeutics, up from -$2.0 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $5.8 million in Q2 2022, with the low at -$6.1 million in Q4 2024.
  • Average Change in Accured Expenses over 5 years is $251000.0, with a median of -$387500.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses surged 9871.43% in 2021, then tumbled 976.68% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $2.0 million in 2021, then crashed by 120.8% to -$411000.0 in 2022, then surged by 270.07% to $699000.0 in 2023, then crashed by 976.68% to -$6.1 million in 2024, then skyrocketed by 75.29% to -$1.5 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$1.5 million, -$2.0 million, and -$3.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.